Cancer-related DNA changes may appear in blood years before diagnosis

	Prostate Cancer
	The latest prostate cancer news from News Medical

	Cancer-related DNA changes may appear in blood years before diagnosis Researchers found that genome-wide plasma cfDNA methylation profiles collected before diagnosis contained early molecular signatures associated with future prostate and breast cancer, with prostate silencer methylation providing the stronger risk stratification.

	Researchers find how prostate tumors reshape the immune microenvironment Researchers at The University of Texas MD Anderson Cancer Center have identified a previously unknown pathway that prostate tumors leverage to suppress the immune system by reshaping the tumor microenvironment to resist treatment.

			$Hypofractionated radiotherapy for prostate cancer matches conventional treatment outcomes$ Hypofractionated radiotherapy for prostate cancer matches conventional treatment outcomes Men with high-risk prostate cancer have a higher likelihood of having residual disease following prostatectomy and may require radiation therapy after surgery, particularly when PSA levels begin to rise. Conventional postprostatectomy radiotherapy (COPORT) is typically delivered over 37 fractions, while hypofractionated postprostatectomy radiotherapy (HYPORT) delivers a slightly lower total radiation dose over just 25 fractions.

			Blood test detects more cancers when added to standard screening A single blood draw that screens for more than 50 cancers substantially increased cancer detection when added to standard screening, identifying cancers that otherwise might have gone undetected until later stages, according to a new study from the Oregon Health & Science University Knight Cancer Institute.

			Scientists reveals how cancer-causing p53 mutations remain invisible to the immune system One of the biggest challenges in cancer immunotherapy may not be that immune cells are too weak, but that some tumors give them too little to see.

	Five-treatment radiation provides excellent long-term prostate cancer control Five-treatment stereotactic body radiation therapy (SBRT) provided excellent long-term cancer control with fewer urinary and sexual side effects than surgery in the first randomized trial to directly compare the treatments for localized prostate cancer.

	Specialized imaging technique detects most clinically relevant prostate cancers An elevated PSA level in the blood may indicate prostate cancer, but does not yet allow for a definitive diagnosis.

	MD Anderson researchers showcase new findings in radiation oncology at ASTRO 2026 Experts from The University of Texas MD Anderson Cancer Center will present nearly 70 abstracts at the 2026 American Society for Radiation Oncology (ASTRO) Annual Meeting.

	UCLA researchers present new radiation advances at ASTRO 2026 Physicians and scientists from the UCLA Health Jonsson Comprehensive Cancer Center will share new research and clinical trial findings at the 2026 American Society for Radiation Oncology (ASTRO) Annual Meeting, including studies on new treatment approaches for prostate, bile duct and head and neck cancers, personalized radiation therapy based on genetic risk, and advances in targeted radiation and radioligand therapy designed to improve cancer...

	Leica Biosystems brings Tempus pathology products to Aperio AI Store, accelerating AI-powered capabilities for oncology research The Aperio AI Store integrates Tempus' AI applications, transforming complex pathology images into research insights and accelerating cancer diagnostics.

	Improving PSA testing beyond traditional LFAs PSA testing with Bright-Dtech™ nanoparticles and ScanLater® technology delivers greater sensitivity and precision than conventional LFAs.

	High-Precision PSA Testing with Advanced Detection Technology PSA testing combines Bright-Dtech™ nanoparticles and ScanLater® technology to improve assay sensitivity and analytical performance.

	Neutrophil Activation by NMU Blocks Cytotoxic T Cell Tumor Infiltration A new study from The Wistar Institute has found a link between the nervous system and the rapid development of neuroendocrine prostate cancer (NEPC), an aggressive form of the disease.

	Researchers Reveal How p53 Tumor-Suppressor Protein Hide From T Cells One of the biggest challenges in cancer immunotherapy may not be that immune cells are too weak, but that some tumors give them too little to see.

	Cancer-Associated Fibroblasts Construct Physical Barriers Limiting Antitumor T Cell Infiltration Researchers at The University of Texas MD Anderson Cancer Center have identified a previously unknown pathway that prostate tumors leverage to suppress the immune system by reshaping the tumor microenvironment to resist treatment.

	Prostate cancer biology helps identify hormone therapy candidates A recent analysis of the NRG-RTOG 0534 "SPPORT" clinical trial evaluated the Luminal B (LumB) molecular subtype using the PAM50 genomic classifier to determine whether tumor biology could help identify patients most likely to benefit from hormone therapy.

Why did you receive this email?
You are receiving this email because you subscribed to updates from AZoNetwork UK Ltd. on one of our websites and requested to be notified of additional information.

Unsubscribe or Update Notification Preferences

Contact | About | Privacy Policy

- - - - - -

Registered Address:
AZoNetwork UK Ltd.,

Manchester | Sydney

Copyright © 2000-2026